Company Description
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Its lead product candidate is ELI-002, a multivalent lymph node–targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node–targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers.
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Robert Connelly |
Contact Details
Address: 451 D Street, 5th Floor Boston, Massachusetts 02210 United States | |
| Phone | (857) 209-0050 |
| Website | elicio.com |
Stock Details
| Ticker Symbol | ELTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $0.00 |
| CIK Code | 0001555192 |
| CUSIP Number | 28657F103 |
| ISIN Number | US28657F1030 |
| Employer ID | 45-2966790 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert T. Connelly | Chief Executive Officer, President and Director |
| Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D. | Founder and Independent Director |
| Dr. Peter DeMuth Ph.D. | Chief Scientific Officer |
| Dr. Christopher M. Haqq M.D., Ph.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Dr. Darrell J. Irvine Ph.D. | Co-Founder, Consultant, Board Observer and Chairman of Scientific Advisory Board |
| Dr. Preetam Shah M.B.A., Ph.D. | Chief Strategy and Financial Officer and Treasurer |
| Megan C. Filoon | General Counsel, Secretary and Compliance Officer |
| Esther Welkowsky | Senior Vice President of Clinical Development |
| Joy Seymour | Vice President and Head of Regulatory Affairs |
| Dr. Thian Kheoh Ph.D. | Senior Vice President of Biometrics |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 2, 2022 | D/A | Filing |
| Sep 13, 2022 | RW | Filing |
| May 27, 2022 | D | Notice of Exempt Offering of Securities |
| Nov 18, 2021 | D/A | Filing |
| Nov 12, 2021 | D/A | Filing |
| Oct 19, 2021 | D | Notice of Exempt Offering of Securities |
| Jul 13, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 29, 2021 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jun 28, 2021 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 9, 2021 | DRS/A | [Amend] [Cover] Draft Registration Statement |